BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8608665)

  • 21. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
    Silberberg J; Racine N; Barre P; Sniderman AD
    Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.
    Morris KP; Skinner JR; Hunter S; Coulthard MG
    Arch Dis Child; 1993 May; 68(5):644-8. PubMed ID: 8323333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of recombinant human erythropoietin (r-HuEPO) on left ventricular mass and left ventricular hemodynamics in hemodialysis patients.
    Minagawa T; Hirano T; Takada N; Ishiguro M; Ohtsuka H
    Nihon Jinzo Gakkai Shi; 1994 Aug; 36(8):934-41. PubMed ID: 7933670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
    Stivelman JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of erythropoietin on blood pressure.
    Raine AE; Roger SD
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):76-83. PubMed ID: 1928084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 28. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
    Yamakado M; Umezu M; Nagano M; Tagawa H
    Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [An echocardiographic study of the left ventricular functional indices in pediatric patients on hemodialysis and in treatment with recombinant human erythropoietin (r-HuEPO)].
    Seracini D; Pollini I; Lavoratti GC; Pela I; Materassi M; Danti D; De Simone L; Favilli S; Manetti A
    Pediatr Med Chir; 1994; 16(4):389-92. PubMed ID: 7816703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. r-HuEPO treatment of anemia associated with multiple myeloma and ESRD.
    Van der Niepen P; Sennesael J; Verbeelen D
    Clin Nephrol; 1993 Feb; 39(2):113. PubMed ID: 8448915
    [No Abstract]   [Full Text] [Related]  

  • 32. [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients].
    Kinugasa E; Nabeshima K; Niikura K; Kawabe S; Akizawa T; Kitaoka T; Koshikawa S
    Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1109-16. PubMed ID: 2287103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of erythropoietin to treat anaemia in end-stage renal disease.
    Ellis P; Ellis JA
    Prof Nurse; 1995 Apr; 10(7):448-50. PubMed ID: 7724635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia.
    Müller R; Steffen HM; Brunner R; Saric J; Pollok M; Baldamus CA; Kaufmann W
    Clin Invest Med; 1991 Dec; 14(6):614-22. PubMed ID: 1665406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
    Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.
    Barlogie B
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):25-7. PubMed ID: 8153675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.